dabigatranhoz

Dabigatran is an anticoagulant medication used to prevent and treat blood clots in patients with non-valvular atrial fibrillation (AF), acute coronary syndrome (ACS), and other conditions that increase the risk of blood clots. It is a direct thrombin inhibitor, meaning it works by blocking the action of thrombin, an enzyme that plays a crucial role in blood clotting. Dabigatran is available in two forms: dabigatran etexilate, which is an oral medication, and dabigatran, which is administered intravenously.

Dabigatran etexilate is typically prescribed once daily, with or without food, and is known for its once-daily dosing regimen, which can improve patient adherence. The medication is generally well-tolerated, with common side effects including nausea, diarrhea, and bleeding. Serious side effects can include severe bleeding, which may require medical intervention.

Dabigatran is indicated for use in patients who are at high risk of stroke or systemic embolism due to AF, and in patients with ACS who are at high risk of ischemic events. The medication is not recommended for use in patients with mechanical heart valves or those who have had recent major surgery or trauma.

Dabigatran is available under the brand name Pradaxa and is manufactured by Boehringer Ingelheim. The medication is subject to strict regulatory oversight to ensure its safety and efficacy. Patients taking dabigatran should be monitored for signs of bleeding and should follow their healthcare provider's instructions for use and dosage.